Soleno Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing novel therapeutics for the treatment of rare diseases. The Company’s lead product candidate, diazoxide choline extended-release tablets (DCCR), is for the treatment of Prader-Willi syndrome (PWS) in individuals four years and older who have hyperphagia. DCCR contains diazoxide choline, a potent ATP-sensitive potassium (KATP) channel activator. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine. Its proposed mode of action, with targets in the brain, pancreas and fat tissue, has the potential to broadly impact complex diseases like PWS to reduce appetite, reduce food-seeking, decrease insulin and leptin resistance, and reduce body fat. The Company has Breakthrough Therapy and Fast-Track designations in the United States and Orphan Drug designations in the United States and European Union.
BörsenkürzelSLNO
Name des UnternehmensSoleno Therapeutics Inc
IPO-datumOct 23, 2014
Gegründet am1999
CEODr. Anish Bhatnagar, M.D.
Anzahl der mitarbeiter92
WertpapierartOrdinary Share
GeschäftsjahresendeOct 23
Addresse100 Marine Parkway, Suite 400
StadtREDWOOD CITY
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl94065
Telefon16502138444
Websitehttps://soleno.life/
BörsenkürzelSLNO
IPO-datumOct 23, 2014
Gegründet am1999
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten